Analysis reveals promising roles of RNA-derived small RNAs in hepatocellular carcinoma, suggesting needs for methodologies and validation in precision cancer treatment.
Although tsRNAs show great promise in HCC diagnosis, prognosis, and therapy, clinical translation remains hindered by gaps in mechanistic understanding, technical challenges in detection, and a lack of large-scale validation. Overcoming these limitations through standardized methodologies and multi-omics integration could unlock their full potential in precision cancer medicine.
No takes yet. Share an insight, caveat, or question.
Abdelhamid et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: